Piramal Pharma Limited PPLPHARMA.NS · Stock Open Piramal Pharma Limited in new tab

203.01 INR

Add to portfolio

EPS

-2.35

P/B

3.22

ROE

-4.00

Beta

0.34

Target Price

233.27 INR

1M 6M YTD 1Y 2Y 5Y Max

Loading chart...

DCF Valuation

Tweak assumptions to recompute fair value for Piramal Pharma Limited (PPLPHARMA.NS)

Currency: INR

DCF Assumptions

Revenue growth (YoY) 0.10 Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).

EBITDA margin 0.30 Decimal (e.g., 0.30 = 30%).

Capex (% Revenue) 0.04 Decimal (e.g., 0.04 = 4%).

Tax rate 0.20 Decimal (e.g., 0.20 = 20%).

Terminal growth (g, %) 3% Percent number (e.g., 3 = 3%).

Cost of Equity (%) 10% Percent number (e.g., 10 = 10%).

Cost of Debt (%) 5% Percent number (e.g., 5 = 5%).

DCF Result

Fair Value (DCF)

—

Current Price

—

Upside

—

WACC

—

Terminal PV

—

Σ PV of FCFs

—

Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Piramal Pharma Limited Analysis (PPLPHARMA.NS)

Official Website Stock

Is Piramal Pharma Limited a good investment? Piramal Pharma Limited (PPLPHARMA.NS) is currently trading at 203.01 INR. Market analysts have a consensus price target of 233.27 INR. This suggests a potential upside from current levels.

Earnings Schedule: Piramal Pharma Limited is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is 4.07.

Investor FAQ

Does Piramal Pharma Limited pay a dividend?

No, it does not currently pay a dividend.

What asset class is Piramal Pharma Limited?

Piramal Pharma Limited is classified as a Stock.

When is the next earnings date?

The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of -2.35.

Company Profile

Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing; offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain management drugs, and other generic and speciality products; and analgesics, skin care, vitamin and mineral supplement, kids' wellness, digestives, and women's health, as well as geriatric care. In addition, the company operates as a contract development and manufacturing organization, providing process development, scale-up, and GMP manufacturing services for vaccines and biologics. The company was incorporated in 2020 and is based in Mumbai, India.

Trades

Dividend History paid per year (INR)

Historical Dividends

Year	Total Dividends
▸2025	0.14 INR
Aug. 29, 2025	0.1400
▸2024	0.11 INR
July 26, 2024	0.1100

Fundamentals

2026 © AllInvestView

Twitter YouTube Reddit Feature Requests Changelog Support Pricing Help

Support email: [email protected]

Terms of Service | Privacy Policy

Free Trackers · Dividend Apps · Tax Reporting · UK · Australia · Germany · Guides · Ticker Logos

Stock Directory · Financial Glossary · Portfolio Templates · Top Dividend Stocks · Investing in US · Investing in UK · Import Guides · Stock Comparison · Earnings Recaps

Data disclaimer: AIV (AllInvestView) assumes no liability for the information presented. Users are encouraged to exercise caution and carefully consider the accuracy, completeness, and relevance of the information provided.

It's important to remember that our website should complement your independent market research rather than replace it. The past performance of assets should not be regarded as a guarantee of future results. AllInvestView is not a registered investment advisor or broker/dealer, and the information presented here is for educational and informational purposes only. We value your trust and are committed to providing you with valuable market insights while emphasizing the importance of responsible decision-making in your investment journey.